NURPF (NURPF) Stock Price & Analysis
NURPF (NURPF) rose 0.00% to USD 8.88 as of June 10, 2026 at 03:50 UTC, according to Nexqual real-time market data.
NURPF last closed at USD 8.88; the session ranged USD 9.25–9.25 on volume of 250 shares. Market capitalization is $1.12B, with a 52-week range of USD 7.7–14.8 (PNK). Source: Nexqual, June 10, 2026 at 03:50 UTC.
Key Statistics (as of June 10, 2026 at 03:50 UTC)
| Price | USD 8.88 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 8.88 |
| Open | USD 9.25 |
| Day Range | USD 9.25 – 9.25 |
| 52-Week Range | USD 7.7 – 14.8 |
| Volume | 250 shares |
| Market Cap | $1.12B |
| Exchange | PNK |
Technical Analysis (NURPF)
Nexqual's technical model rates NURPF "BUY" based on 5 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 03:50 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 8.73) |
| MACD | 0.02 (positive) |
Analyst Ratings (NURPF)
Wall Street analysts rate NURPF "None", per Nexqual as of June 10, 2026 at 03:50 UTC.
| Consensus Rating | None |
|---|
Earnings (NURPF)
Source: Nexqual, June 10, 2026 at 03:50 UTC.
Financials & Fundamentals (NURPF)
| Total Revenue | $64.65M |
|---|---|
| Revenue Growth (YoY) | -80.90% |
| Gross Margin | +43.71% |
| Operating Margin | +30.63% |
| Profit Margin | +47.08% |
| ROE | +8.67% |
| Current Ratio | 76.6 |
| Total Cash | $296.12M |
| Total Debt | $0 |
| Free Cash Flow | $116.98M |
Source: Nexqual, June 10, 2026 at 03:50 UTC.
Financial Health Score (NURPF)
Nexqual rates NURPF's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:50 UTC.
| Growth | Critical — Revenue -70% YoY (annual), sharp decline |
|---|---|
| Profitability | Strong — Gross margin 44%, operating 31% |
| Balance Sheet | Mixed — $296M cash, no debt |
| Cash Flow | Strong — FCF $117M, 181% margin |
| Efficiency | Mixed — ROE 9%, ROA 3.7% |
Ownership (NURPF)
| Insider Ownership | +13.39% |
|---|---|
| Institutional Ownership | +25.77% |
| Shares Outstanding | 126.32M |
| Float | 109.68M |
Source: Nexqual, June 10, 2026 at 03:50 UTC.
Leadership (NURPF)
NURPF is led by Jonathan Charles Pilcher A.C.A., B.Sc., BSc (Hons), F.C.A., CEO, MD & Executive Director, per Nexqual as of June 10, 2026 at 03:50 UTC.
| CEO, MD & Executive Director | Jonathan Charles Pilcher A.C.A., B.Sc., BSc (Hons), F.C.A. |
|---|---|
| CFO & Company Secretary | Lauren Frazer C.A. |
Major Backers & Investors (NURPF)
Notable institutional backers of NURPF include DFA INVESTMENT TRUST CO-The Asia Pacific Small Company Series, American Century ETF Trust-Avantis International Small Cap Value ETF, -Polar Capital International Small Company Fund, according to Nexqual as of June 10, 2026 at 03:50 UTC.
Active Investors
| Investor | Stake |
|---|---|
| DFA INVESTMENT TRUST CO-The Asia Pacific Small Company Series | 0.4% |
| American Century ETF Trust-Avantis International Small Cap Value ETF | 0.34% |
| -Polar Capital International Small Company Fund | 0.21% |
| JNL Series Trust-JNL Multi-Manager International Small Cap Fund | 0.21% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.35% |
| BlackRock | 1.23% |
Source: Nexqual, June 10, 2026 at 03:50 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TLPPF | Telix Pharmaceutical Ltd. | USD 9.41 | ▼ 0.95% |
| CLVLY | Clinuvel Pharmaceuticals Ltd. | USD 6.36 | ▼ 3.64% |
| PTCHF | PureTech Health PLC | USD 1.8 | ▼ 3.33% |
| CLVLF | Clinuvel Pharmaceuticals Ltd. | USD 6.4 | ▲ 0% |
| UCBJY | UCB S.A. | USD 151.74 | ▲ 1.47% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:50 UTC. This page is informational and not investment advice.